Immunocore Open menu Publications Accelerating the time from bench to bedside Home / Our science / Publications Categories: All TCR engineering ImmTAC molecules Uveal melanoma tebentafusp (IMCgp100) ImmTAV molecules Safety Target identification and validation Further reading Clear search Authors Title Links/Downloads Middleton M.R. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potentially Activated Antitumour Immune Responses in Patients with Metastatic Melanoma View Fergusson J.R. Epub ahead of print: Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells View Coles C.H., Mulvaney R.M. T cell receptors with distinct specificity profiles use different binding modes to engage an identical peptide-HLA complex. J Immunol. 2020 Apr 1;204(7):1943-1953. View Damato B.E. Tebentafusp: T Cell Redirection for the Treatment of Advanced Uveal Melanoma. Cancers 2019 Jul 11;11(7). pii: E971. View Madura F. TCR-induced alteration of primary MHC peptide anchor residue. Eur. J. Immunol. 2019 Jul;49(7):1052-1066. View Lowe K.L. Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treat Rev. 2019 Jul;77:35-43. View Dobrzycki T., Ciuntu A. Assessing the potency of T cell redirecting therapeutics using in vitro cancer cell killing assays. Immuno-Oncology: Cellular and Translational Approaches, Springer Methods. 2019 Sato T, et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T cell based toxicity and preliminary efficacy in advanced uveal melanoma (2017) ASCO. Abstract News article Carvajal, R, et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (2017) SITC. Abstract News article Boudousquie C. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells (2017) Immunology. 152(3):425-438. PubMed previous 1 2 3 4 next IN THIS SECTION Our science Pipeline Scientific Advisory Board Immunocore About us Our science Our therapy areas For patients Investors/Media Careers Contact us Privacy and Social Media Guidelines Cookies Payments and Disclosures Clinical trials Gender Pay Report ©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the Cookie notice I Accept